MorphoSys Granted Further Patent on its Core Antibody Technology in Japan
(Thomson Reuters ONE) -
MorphoSys AG / MorphoSys Granted Further Patent on its Core Antibody Technology in Japan processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the
Japanese Patent Office has granted a new patent providing extended protection
for the Company's core technology HuCAL. The new patent (JP 4436457) covers the
production and design of an antibody library based on phage display. Currently,
the Company is prosecuting more than 35 different proprietary patent families
worldwide, in addition to about the same number of patent families the Company
is pursuing in cooperation with its partners.
"Important progress was made with our patent portfolio during 2009 and in the
first quarter of 2010, including the issuance of the first Japanese patents
covering our core proprietary technologies HuCAL and CysDisplay," commented Dr.
Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Our growing patent
estate in Asia complements our strong intellectual property portfolio around
HuCAL in other key pharmaceutical markets."
MorphoSys's HuCAL libraries are collections of highly diverse, fully human
synthetic antibodies, whose modular CDR designs facilitate systematic
engineering of antibody properties. The Company's most advanced version of the
technology, HuCAL PLATINUM, provides rapid access to fully human antibodies for
use as research tools, diagnostics and therapeutics.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.
Via its business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is headquartered
in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol
"MOR". For further information, visit http://www.morphosys.com/
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
[HUG#1393713]
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:CDAX,Prime All Share,HDAX,TECH All Share,MIDCAP,TecDAX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release: http://hugin.info/130295/R/1393713/350765.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.03.2010 - 02:30 Uhr
Sprache: Deutsch
News-ID 1011331
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried / München
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 89 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Granted Further Patent on its Core Antibody Technology in Japan
"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
